X
[{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$772.0 million","upfrontCash":"$30.0 million","newsHeadline":"Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. FDA Approved the Phase I\/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16\/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1\/4-1BB Bispecific Antibody Developed by Leads Biolabs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Leads Biolabs
Filters
Companies By Therapeutic Area
Details:
LBL-024 is a bispecific antibody composed of anti-PD-L1 and anti-4-1BB (CD137) antibodies. It binds to PD-L1 with high affinity, blocking the PD-L1/PD-1 immunosuppressive pathway while conditionally activating the 4-1BB costimulatory pathway in the tumor microenvironment.
Lead Product(s):
LBL-024
Therapeutic Area: Oncology
Product Name: LBL-024
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 30, 2024
Details:
LBL-033 is a T-cell engager, bispecific antibody, targeting MUC16-expressing tumor cells and CD3-expressing T cells, which is investigated for treatment for advanced solid tumors including ovarian cancer.
Lead Product(s):
LBL-033
Therapeutic Area: Oncology
Product Name: LBL-033
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 16, 2023
Details:
Under the terms of the agreement, BeiGene will gain the rights for research, development and manufacturing and exclusive commercialization outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.
Lead Product(s):
LBL-007,Toripalimab
Therapeutic Area: Oncology
Product Name: LBL-007
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BeiGene
Deal Size: $772.0 million
Upfront Cash: $30.0 million
Deal Type: Collaboration
December 14, 2021